April 28, 2026 (MLN):  BF Biosciences Limited (PSX: BFBIO) reported a substantial 45% increase in its net profit for the nine months ended March 31, 2026, reaching Rs464.95m compared to Rs320.34m in the corresponding period last year.

Reflecting this strong bottom-line growth, the company's basic and diluted earnings per share (EPS) expanded to Rs5.26 from Rs4.08 in 9MFY25.

The primary catalyst for this profitability was a massive top-line expansion that significantly outpaced direct production costs.

BFBIO’s net revenue surged by an impressive 72% year-on-year, rising to Rs7.24bn from Rs4.21bn.

Concurrently, the cost of goods sold grew at a slower rate of 63%, reaching Rs4.05bn.

This robust revenue volume and favorable cost absorption caused the gross profit to skyrocket by 84%, settling at Rs3.19bn compared to Rs1.74bn in the prior year.

However, the company faced surging operational overheads that consumed a large portion of these gross gains.

Selling and distribution expenses nearly doubled, spiking 97% to a heavy Rs2.13bn.

Administrative expenses also saw a staggering jump, climbing to Rs139.45m from just Rs42.63m last year.

Other expenses increased by 98% to Rs115.92m, while other income remained largely flat, edging up just 3% to Rs94.25m.

Despite the dramatic escalation in operating costs, the sheer strength of the gross margin expansion pushed the profit from operations up by 39% to Rs897.64m.

Below the operating line, BFBIO found substantial relief in debt servicing. Finance costs dropped by a notable 37%, falling to Rs77.49m from Rs122.64m.

Boosted by these savings in financial charges, the profit before income tax registered a strong 55% increase, reaching Rs810.60m.

Even after absorbing a 71% higher income tax expense of Rs345.65m, the company successfully secured its 45% leap in final net profit, comfortably closing the nine-month period at Rs464.95m.

Copyright